As of 12:32 PM on the 12th, Seegene is trading at 222,500 KRW, down 3.6% from the previous day. The trading volume is 1,427,001 shares, which is 84.62% of the previous day's volume. Seegene is known as a developer, manufacturer, and seller of molecular diagnostic reagents.


On November 12, KTB Investment & Securities researcher Kang Ha-young stated, "Due to the persistent nature of infectious diseases, the estimated earnings fluctuate greatly, and there is potential for further upward revisions. However, the future stock price direction is expected to be determined more by external factors such as the development status of COVID-19 vaccines and treatments rather than the magnitude of earnings upgrades. Trading approach recommended." He set Seegene's target price at 260,000 KRW.


Over the past five days, individual investors have net purchased 322,983 shares of Seegene, while foreign and institutional investors have net sold 163,914 shares and 168,411 shares, respectively.



※Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing